Compare ROAD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | CNTA |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.1B |
| IPO Year | 2018 | 2021 |
| Metric | ROAD | CNTA |
|---|---|---|
| Price | $115.80 | $39.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $127.80 | $43.17 |
| AVG Volume (30 Days) | 419.1K | ★ 4.9M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | 29.13 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $785,679,000.00 | $15,000,000.00 |
| Revenue This Year | $27.79 | N/A |
| Revenue Next Year | $10.29 | N/A |
| P/E Ratio | $376.03 | ★ N/A |
| Revenue Growth | ★ 0.31 | N/A |
| 52 Week Low | $83.20 | $10.95 |
| 52 Week High | $141.90 | $40.26 |
| Indicator | ROAD | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 73.18 |
| Support Level | $113.03 | $39.16 |
| Resistance Level | $116.48 | $40.26 |
| Average True Range (ATR) | 5.31 | 0.20 |
| MACD | 0.14 | -0.47 |
| Stochastic Oscillator | 27.74 | 47.54 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.